These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 6233076

  • 1. [Controlled clinical study on 2 antialdosterone diuretics in the nephrotic syndrome].
    Russo R, Schena FP, Colombo Pirola L.
    Clin Ter; 1984 Apr 15; 109(1):23-9. PubMed ID: 6233076
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
    Tempini S, Bellati G, Ideo G.
    Minerva Dietol Gastroenterol; 1984 Apr 15; 30(3):255-61. PubMed ID: 6504374
    [No Abstract] [Full Text] [Related]

  • 4. The use of diuretics in preventing ascites recurrence.
    Arrigoni A, Andriulli A, Gindro T, Verme G.
    Br J Clin Pract; 1988 Mar 15; 42(3):116-20. PubMed ID: 3207572
    [No Abstract] [Full Text] [Related]

  • 5. [Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)].
    Gorbach HC, Bräuninger HJ.
    MMW Munch Med Wochenschr; 1975 Sep 15; 117(37):1483-6. PubMed ID: 810673
    [Abstract] [Full Text] [Related]

  • 6. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M, Cuppone R, Ricci GL.
    Arzneimittelforschung; 1988 Oct 15; 38(10):1492-5. PubMed ID: 3058132
    [Abstract] [Full Text] [Related]

  • 7. Metolazone and spironolactone in cirrhosis and the nephrotic syndrome.
    Lang GR, Westenfelder C, Nascimento L, Dhupelia VB, Arruda JA, Kane RE.
    Clin Pharmacol Ther; 1977 Feb 15; 21(2):234-43. PubMed ID: 319937
    [Abstract] [Full Text] [Related]

  • 8. [Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation].
    Denis B, Dimitriou R, Machecourt J, Wolf JE, Page E, Reboud JP.
    Arch Mal Coeur Vaiss; 1984 Apr 15; 77 Spec No():35-40. PubMed ID: 6428361
    [Abstract] [Full Text] [Related]

  • 9. [Use of potassium canrenoate in cardiosurgery].
    Tufano R, Scopa M, Brando G, Leone D.
    Minerva Anestesiol; 1981 Apr 15; 47(4):149-54. PubMed ID: 7242963
    [Abstract] [Full Text] [Related]

  • 10. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
    Tosti-Croce C, Mantellini R, Fanti P, Sciarra F.
    Minerva Med; 1983 Apr 07; 74(14-15):791-7. PubMed ID: 6339999
    [Abstract] [Full Text] [Related]

  • 11. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S, Buch J.
    Eur J Cardiol; 1979 Aug 07; 10(2):143-9. PubMed ID: 477703
    [Abstract] [Full Text] [Related]

  • 12. [Treatment of advanced respiratory insufficiency using potassium canreonate (Aldactone). Preliminary report].
    Kerjaschki A.
    Wien Med Wochenschr; 1976 Dec 03; 126(49-50):705-7. PubMed ID: 795170
    [No Abstract] [Full Text] [Related]

  • 13. [Effect of potassium canrenoate on arterial pressure, plasma renin activity and urinary aldosterone in essential hypertension].
    Opocher G, Armanini D, Fallo F, Mantero F.
    Boll Soc Ital Cardiol; 1978 Dec 03; 23(10):1757-66. PubMed ID: 400390
    [No Abstract] [Full Text] [Related]

  • 14. [Value of Soludactone in cardiac surgery in adults].
    Fogliani J, Capuccio P, Goudard A, Guillen JC, Monties JR.
    Ann Anesthesiol Fr; 1975 Dec 03; 16(3):189-96. PubMed ID: 241276
    [Abstract] [Full Text] [Related]

  • 15. [Aldosterone antagonists in coronary insufficiency].
    Osswald H.
    Med Klin; 1978 Jan 20; 73(3):84-8. PubMed ID: 622061
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of digitalis toxicity with intravenous potassium canrenoate.
    Gavrilescu G, Cristodorescu R, Deutsch G, Berger E.
    Agressologie; 1977 Jan 20; 18(3):167-71. PubMed ID: 920909
    [No Abstract] [Full Text] [Related]

  • 17. [Use of canrenoate potassium given orally in ascitogenic cirrhosis].
    Sarti F, Milandri GL, Piemontese A, Macchia S, Simoni S, Dal Monte PR.
    Minerva Dietol Gastroenterol; 1984 Jan 20; 30(3):273-80. PubMed ID: 6504377
    [No Abstract] [Full Text] [Related]

  • 18. [Efficacy of canrenoate potassium in hypertensive cardiopathy. Clinical and echocardiographic evaluation].
    Caporicci D, Achilli L.
    Minerva Cardioangiol; 1984 Sep 20; 32(9):581-7. PubMed ID: 6514202
    [No Abstract] [Full Text] [Related]

  • 19. [Therapeutic effect of canrenoate potassium (soldactone) in patients after open-heart surgery].
    Matsuda K, Tatsuta N, Konishi Y, Minami K, Nishiwaki N, Yamasato A, Chiba Y, Ishihara H, Murata S, Shiraishi Y, Muraguchi T, Hikasa Y.
    Nihon Geka Hokan; 1982 May 01; 51(3):519-27. PubMed ID: 7138201
    [No Abstract] [Full Text] [Related]

  • 20. [Interference of canrenoate potassium with plasma renin activity. Note I. Effects of canrenoate potassiumon plasma renin activity in patients with essential hypertension].
    Consolo F, Ferraù O, Pitrone F, Luzza G, Russo A, Virga T.
    Boll Soc Ital Biol Sper; 1975 Dec 30; 51(24):1943-9. PubMed ID: 1231877
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.